McDermott Will & Emery represented REGENXBIO in the transaction. REGENXBIO closed its $1.8 billion strategic partnership with AbbVie to develop and commercialize RGX-314, a potential one-time...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here